Qwen

A Comprehensive Regulatory and Technical Analysis of the Nanoswarm Medical Assistant Framework

Regulatory Classification and Compliance as a High-Risk Medical Device

The proposed nanoswarm medical assistant framework represents a paradigm shift from conventional medical devices, moving towards a fully autonomous, closed-loop therapeutic system. This fundamental characteristic places it squarely within the highest tier of regulatory scrutiny under both the U.S. Food and Drug Administration (FDA) and the European Union's Medical Device Regulation (EU MDR) [34 165]. A thorough analysis of the framework's core functionalities reveals its alignment with specific classification rules that mandate a Class III designation, the most stringent category for medical devices due to their potential for life-sustaining or life-supporting functions [34 35]. Under the EU MDR, the system would almost certainly fall under Article 51(1)(a), which classifies active implantable devices as Class III if they are used in direct contact with the central nervous system or circulatory system, or have a biological effect or are mainly absorbed [32]. Furthermore, Rule 22 of Annex VIII explicitly categorizes active therapeutic devices with an integrated diagnostic function that significantly determines patient management—such as a closed-loop system that autonomously adjusts therapy based on physiological feedback—as Class III [32 38]. The user's framework, with its adaptive intervention logic ($I_{nano}(t)$) triggered by a real-time needs state vector ($\mathbf{U}(t)$), perfectly exemplifies this definition. Similarly, under EU MDR Rule 11, software intended to provide information for diagnosis or therapeutic decisions is classified based on risk; if its decision could lead to death or irreversible health deterioration, it is designated as Class III [82 165]. The nanoswarm's ability to autonomously deliver drugs or perform other therapeutic actions based on biosignal analysis meets this high-risk threshold.

In the United States, the FDA regulates such devices through established pathways like Premarket Approval (PMA) for high-risk products, which require substantial evidence of safety and effectiveness [12 133]. The nanoswarm's nature as a Software as a Medical Device (SaMD) that makes autonomous decisions places it under the purview of the FDA's evolving AI/ML SaMD Action Plan [129 166]. The agency has clarified that AI-driven medical devices are regulated under the same principles as non-AI devices, but with added considerations for algorithmic performance, bias, and lifecycle management [137]. The proposed system's requirement for multi-signature governance and a sandboxed environment for action simulation reflects a design philosophy consistent with the FDA's emphasis on "secure-by-design" principles, which aim to minimize vulnerabilities across the total product lifecycle [85 87]. The regulatory burden associated with a Class III classification is immense, requiring manufacturers to establish and maintain a full Quality Management System (QMS) aligned with ISO

13485, conduct rigorous clinical evaluations supported by extensive data, and implement comprehensive Post-Market Surveillance (PMS) and Post-Market Clinical Follow-up (PMCF) plans [34 84]. For the nanoswarm, this means documenting every aspect of its development, from the selection of the therapeutic gain matrix ($\mathbf{K}$) to the cryptographic protocols securing each intervention, as part of a mandatory Technical File or Pre-Market Approval Application [34 137]. The Summary of Safety and Clinical Performance (SSCP) will be a critical document, summarizing all findings in a way that is understandable to laypersons while providing sufficient detail for regulators [34 84].

Beyond traditional medical device regulations, the framework's reliance on AI introduces a new layer of compliance governed by specific AI-focused guidance. The FDA's 2025 draft guidance on using AI to support regulatory decision-making establishes a seven-step risk-based credibility assessment framework, starting with defining the Context of Use (COU) [134 135]. The COU is foundational, determining the scope and rigor of the model's validation [134]. The nanoswarm's COU would be exceptionally broad, encompassing everything from managing chronic conditions to responding to acute emergencies, necessitating a high level of validation. The framework's explicit equations provide a strong basis for this, allowing for traceability from inputs to outputs—a key requirement for auditors [153]. The concept of a "therapeutic gain matrix" ($\mathbf{K}$) implies a tunable system, which directly invokes the FDA's guidance on Predetermined Change Control Plans (PCCPs) [129]. A PCCP allows manufacturers to pre-specify categories of algorithmic changes and the validation methods required for them, streamlining post-market updates without needing repeated premarket review [137 165]. Any modification to $\mathbf{K}$, for instance, would need to be documented within the PCCP, ensuring that even adaptive changes remain within a predefined, safe boundary. Furthermore, the system's complexity, especially its inclusion of emotional signals ($Emo(t)$), raises significant concerns about algorithmic bias. The FDA requires systematic evaluation of training data for demographic representation and performance analysis across subgroups to mitigate fairness issues [130 137]. The framework must therefore be developed within a quality system that includes processes for identifying, mitigating, and monitoring potential biases throughout the AI's lifecycle [137].

The table below summarizes the alignment between the nanoswarm framework and key regulatory requirements, highlighting areas of strong correspondence and potential challenges.

Regulatory Domain	Key Requirement / Guideline	Alignment with Nanoswarm Framework
EU MDR / FDA SaMD	Class III Classification (High Risk)	Autonomous intervention based on biosignals directly maps to MDR Rules 11 & 22 and FDA PMA pathways. [32 34 38 165]
AI Credibility	Risk-Based Credibility Assessment (FDA)	The explicit mathematical formulation of $\mathbf{U}(t)$ and $I_{nano}(t)$ facilitates rigorous validation and traceability required for a high-risk AI model. [134 135 153]
AI Lifecycle		

Regulatory Domain	Key Requirement / Guideline	Alignment with Nanoswarm Framework
	Predetermined Change Control Plan (PCCP) (FDA)	The tunable nature of the therapeutic gain matrix ($\mathbf{K}$) necessitates a PCCP to manage post-market updates safely and efficiently. [129 137 165]
AI Fairness	Bias Mitigation (FDA/ Ethics)	The inclusion of diverse biosignals, including emotional states, requires a robust process for assessing and mitigating algorithmic bias across different populations. [130 137 148]
Cybersecurity	Secure Product Development (FDA 2025)	Multi-signature governance and cryptographic hashing align with requirements for secure design, access control, and event logging. [85 87 138]
Data Privacy	HIPAA/GDPR (Patient Sovereignty)	Blockchain-based dynamic consent and cryptographic audit trails support patient control over data use and meet privacy mandates. [100 103 183]

Ultimately, the nanoswarm framework cannot be viewed merely as a piece of software; it is a blueprint for a regulated medical product whose entire lifecycle—from conception to post-market surveillance—is subject to intense regulatory oversight. The claim of adhering to "FDA Nanotech 2025" and "EU MDR III" is not aspirational but a direct consequence of its design. Every component, from the state vector to the cryptographic signatures, must be treated as a critical element of the technical documentation required for regulatory approval, demanding a parallel track of development focused on generating the evidence needed to prove safety and efficacy to the satisfaction of global health authorities.

The Mathematical Framework as an Auditable Artifact for Compliance

The elegance and rigor of the proposed mathematical framework serve a dual purpose: they provide a principled method for designing the nanoswarm's intelligence, and they create a structured, formal artifact that can be systematically evaluated and audited to meet stringent regulatory demands. Each equation and logical construct within the framework translates abstract regulatory principles into concrete, verifiable components, forming the backbone of the Quality Management System (QMS) and the evidence package for premarket submission. The Real-Time Needs State Vector, $\mathbf{U}(t)$, is the foundation of the device's monitoring capability. Its formal definition—comprising normalized clinical ranges for hydration, nutrition, stress, wound status, toxins, drug dosing, pain, and emotion—directly addresses the FDA's requirement for a detailed Data Collection Protocol (DCP) [153]. Such a protocol must specify the exact inputs, data sources, collection conditions, and handling procedures for any data used to train or operate an AI model [153]. By defining $\mathbf{U}(t)$ with precise units and normalization, the framework provides a clear operational definition of the DCP, reducing ambiguity and ensuring consistency. The inclusion of an emotional signal ($\boldsymbol{Emo}(t)$) pushes the device beyond

simple physiological monitoring into personalized medicine, but also introduces complexities related to the objectivity and reproducibility of such measurements, which must be thoroughly validated and justified in the QMS documentation [30 59]. The entire vector represents the input to the control system, and its integrity is paramount for the device's safety and effectiveness.

The Adaptive Intervention Functional, $I_{nano}(t)$, is the core of the device's therapeutic action. Its formulation as a feedback control law,
I_{nano}(t) = \mathbf{K} \cdot [\mathbf{U}<em threshold>{desired} - \mathbf{U}(t)
would be considered a modification, and its impact on the system's performance and safety would need to be assessed according to a predefined plan. The mathematical clarity of the framework ensures that these changes are well-defined and their consequences can be systematically analyzed, satisfying the FDA's demand for traceability and control over adaptive systems [153].})
, is a classic control-theoretic approach applied to a biomedical context <sup><a class
\mathbf{K}
, make this possible. The FDA's guidance on PCCPs requires manufacturers to define th
\mathbf{K

Perhaps the most innovative and regulationally significant component is the Cryptographically Anchored Consent and Audit Chain. This system transforms the abstract concept of patient consent into a concrete, tamper-proof digital record. By using a hash function like BLAKE3-512 to link each intervention to a time index, a transaction type, and a multi-signature approval, the framework creates an immutable ledger of all nanoswarm activities [17 173]. This directly fulfills the HIPAA Security Rule's mandate for mechanisms that record and examine activity in systems containing electronic Protected Health Information (ePHI) [72]. An audit trail built on this principle provides a complete, chronological record of every action taken by the nanoswarm, who authorized it, and when, which is invaluable for incident investigation and compliance verification [22 72]. More importantly, this architecture operationalizes the concept of dynamic consent, where patients can actively manage their data usage preferences over time [100]. The system's response to revoked consent—triggering an immediate safety rollback, $R_{rollback}$—is a critical safety feature that empowers patients and aligns with modern bioethical principles of autonomy [100 103]. This is particularly relevant given that a majority of patients express a desire for ongoing control over their data, even if they do not frequently change their settings [103]. The use of blockchain technology for this purpose is a forward-thinking approach that addresses the inherent conflict between data immutability and the 'right to erasure' under GDPR, by storing only metadata and pointers on-chain while keeping sensitive ePHI off-chain in a HIPAA-compliant environment [183 185].

Finally, the Environmental and Emotional Sensing module, $H_{risk}(t)$, embodies a proactive risk-management philosophy that aligns with the FDA's Total Product Life Cycle (TPLC) approach [166]. Instead of waiting for a hazard to manifest, the system anticipates risks by integrating environmental and psychological factors into its decision-making loop. This predictive capability is crucial for a device operating autonomously within a complex biological system. The framework's design inherently generates vast amounts of longitudinal data, which can be used for Real-World Evidence (RWE) generation—a cornerstone of modern regulatory science [156]. RWE derived from the nanoswarm's operation could provide invaluable insights into long-term safety, effectiveness in

diverse populations, and rare adverse events, supporting post-market surveillance and informing future device improvements [156 167]. The entire mathematical framework, from the state vector to the risk assessment function, can be implemented within a Digital Twin environment. These virtual models allow for extensive, non-clinical testing of the closed-loop system under a wide range of simulated physiological scenarios, providing a powerful tool for validating the device's safety and performance before it is ever tested in humans [150 151]. By creating a formal, mathematically grounded system, the framework provides the essential building blocks for a comprehensive compliance strategy, demonstrating not just that the device works, but that it works safely, reliably, and in accordance with the letter and spirit of global medical device regulations.

Biosensing and Actuation: Bridging Theory with Clinical Reality

While the mathematical framework provides a robust theoretical foundation, the ultimate success and safety of the nanoswarm medical assistant hinge on the practical feasibility of its constituent hardware: the biosensors for monitoring and the actuation mechanisms for intervention. The transition from the abstract state vector $\mathbf{U}(t)$ to a tangible, reliable measurement of a patient's physiological state presents significant engineering and clinical challenges. The framework calls for sensors capable of continuously and accurately tracking hydration, nutrition, stress, wound status, toxin levels, drug dosing, pain, and emotional state. Current advancements in wearable and implantable biosensors are making some of these goals achievable, but collectively, the requirements push the boundaries of existing technology. For instance, electrochemical sensors can detect metabolites like glucose and lactate, and electrolytes like sodium and potassium in sweat, offering a non-invasive window into metabolic and hydration status [118 120 123]. However, sweat composition is highly variable, influenced by factors like sweat rate, skin contaminants, and individual differences, requiring sophisticated calibration and sensor fusion techniques to correlate readings with blood-based clinical metrics [120 123]. Similarly, while EEG, ECG, and EMG technologies exist for monitoring brain, heart, and muscle activity, they are often susceptible to noise, motion artifacts, and crosstalk, limiting their reliability in ambulatory settings [60]. Achieving the fidelity required for the state vector would necessitate a multi-modal sensing architecture, where data from various types of sensors (e.g., biochemical, electrophysiological, thermal) are fused using machine learning algorithms to build a coherent and accurate picture of the user's overall state [17 140]. This integration is a complex task, requiring careful consideration of data preprocessing, feature extraction, and model validation to ensure the resulting state estimate is clinically meaningful and trustworthy [114].

The second major challenge lies in actuation—the ability of the nanoswarms to execute the intervention calculated by the control function $I_{nano}(t)$. The framework assumes a perfect execution of actions ranging from targeted drug delivery to mechanical tissue repair. Current research in micro/nanorobotics demonstrates several promising avenues for achieving this. Magnetic actuation is one of the most mature approaches, allowing for precise, non-invasive three-dimensional control of magnetic nanoparticles using external field generators like Helmholtz coils [96 112]. This method has been shown to guide swarms through complex environments like vasculature and enable tasks like thrombolysis [98 99]. Acoustic actuation, using ultrasound waves, offers another powerful tool for manipulating swarms, enabling reversible assembly and disassembly, and even powering

propulsion at the microscale [97 110]. Hybrid systems combining magnetic steering with acoustic manipulation show great promise for navigating challenging biological environments [113]. Chemical actuation, where motors are propelled by catalytic reactions with fuels present in the body, such as urea or hydrogen peroxide, represents a third frontier [96 116]. Enzyme-powered nanomotors, for example, have demonstrated the ability to self-propel in viscous media like mucus and accumulate in tumor sites, overcoming biological barriers that impede passive nanoparticles [109 116]. These advanced propulsion systems are crucial for delivering therapies deep within tissues.

Despite these advances, significant hurdles remain before any of these actuation methods can be deployed for a high-risk medical device like the nanoswarm. Scalability is a primary concern; manufacturing billions of identical, functional nanorobots consistently is a monumental challenge [12]. Biocompatibility is equally critical; materials must be non-toxic, non-immunogenic, and ideally, biodegradable to avoid long-term accumulation and potential complications [105 143]. One of the most significant biological barriers is the formation of a "protein corona," where proteins in the bloodstream adsorb onto the nanoparticle surface, altering its intended function and potentially triggering an immune response [53 105]. Overcoming this requires sophisticated surface chemistry and functionalization strategies. Furthermore, ensuring complete removal or degradation of the nanoswarms after their mission is complete is a non-negotiable safety requirement [143]. Some designs incorporate self-disassembly mechanisms, where an external stimulus like a magnetic field causes the swarm to break apart into individual particles that can be cleared by the body's natural processes, a crucial fail-safe that must be built into any viable platform [98]. The path from laboratory proof-of-concept to clinical-grade deployment involves extensive preclinical testing to characterize the nanomaterials, assess their toxicity, and demonstrate their efficacy and safety in animal models, a process that can take many years and cost millions of dollars [12 31]. Therefore, while the mathematical framework is visionary, its realization is contingent upon breakthroughs in materials science, nanofabrication, and biomedical engineering that can overcome these formidable practical challenges.

Cybersecurity, Data Privacy, and Governance Architecture

The nanoswarm framework's emphasis on a multi-layered governance architecture, featuring multi-signature approvals and continuous sandboxing, is not merely a design preference but a fundamental necessity for meeting the stringent cybersecurity and data privacy standards demanded by modern healthcare regulations. The system's interconnected nature, involving continuous data flow from biosensors, autonomous decision-making, and remote communication, makes it a prime target for cyberattacks that could compromise patient safety and data confidentiality [138 191]. The framework's architecture directly addresses the core tenets of the FDA's June 2025 Final Guidance on Cybersecurity in Medical Devices, which codifies cybersecurity as a critical component of a device's safety and effectiveness [85 87]. The requirement for a Software Bill of Materials (SBOM) is implicitly met by the formalized ALN programming language, which would serve as a complete inventory of all software components and their interdependencies [93 138]. The SBOM is essential for vulnerability management, allowing manufacturers and users to quickly identify and patch known security flaws in

the underlying libraries and dependencies [85]. The governance layer's multi-signature requirement, mandating at least three council members to approve an action, enforces a principle of separation of duties and prevents any single point of failure or malicious intent from authorizing a harmful intervention [180]. This distributed authorization model enhances accountability and aligns with best practices for securing critical systems.

The cryptographic audit chain, anchored by the BLAKE3-512 hash function, provides a robust solution for data integrity and forensic visibility. This approach creates an unalterable log of all nanoswarm activities, which is critical for detecting unauthorized access or malicious modifications [17 183]. This is particularly important for complying with the HIPAA Security Rule, which requires covered entities to implement mechanisms to record and examine activity in systems containing ePHI [72]. The system's architecture, which stores sensitive patient data off-chain while recording hashes and metadata on a private blockchain, is a best-practice hybrid model that balances the benefits of immutability with the privacy requirements of HIPAA and GDPR [183 185]. This structure effectively sidesteps the "right to erasure" challenge posed by public blockchains, as the actual PHI remains in a controlled, off-chain environment where it can be managed in accordance with legal requirements [183]. The use of smart contracts can further automate consent management, triggering alerts or disabling access when a patient revokes consent, thus operationalizing the dynamic consent model and giving patients unprecedented control over their own data [139 142]. This aligns with growing patient expectations for greater transparency and control over how their health information is used [103].

The proposed rollback mechanism triggered by revoked consent is a critical safety feature that demonstrates a deep understanding of the need for fail-safe controls in autonomous systems. This mechanism must be complemented by other robust fail-safes to ensure patient safety in the event of a malfunction, hacking attempt, or unforeseen physiological reaction. Passive fail-safes, such as designing the nanoswarming agents for complete biodegradability or for automatic disassembly after a set period or upon mission completion, are essential to prevent long-term retention in the body [98 143]. Active fail-safes, such as remote deactivation commands sent via electromagnetic or ultrasound signals, provide an additional layer of emergency control for clinicians [143]. The governance architecture must also extend beyond the technical system to include organizational policies and procedures. A multidisciplinary governance committee, comprising clinicians, data scientists, ethicists, and IT security experts, is necessary to oversee the system's development and deployment, ensuring that ethical considerations are addressed and that there is clear accountability for the system's actions [24 148]. This committee would be responsible for reviewing the council's decisions, auditing the system's performance, and managing incidents. The entire framework, from its cryptographic foundations to its multi-layered governance and safety protocols, constitutes a comprehensive defense-in-depth strategy. It moves beyond a reactive security posture to a proactive, secure-by-design philosophy that is increasingly being mandated by regulators worldwide. By embedding security and privacy into the very fabric of the system's design, the nanoswarm framework sets a new standard for the development of next-generation medical technologies.

A Strategic Pathway for Clinical Translation and Validation

Translating the sophisticated mathematical framework of the nanoswarm medical assistant into a clinically approved and commercially viable product requires a meticulously planned, multi-stage pathway that integrates engineering, regulatory science, and clinical research. The journey begins not with code, but with a robust Quality-by-Design (QbD) program. This approach, recommended for nanomedicine development, focuses on defining Critical Quality Attributes (CQAs) early in the process and understanding how material properties and process parameters influence them to ensure final product quality, consistency, and safety [12 105]. For the nanoswarm, this means establishing strict specifications for the size, shape, surface charge, and chemical composition of the nanorobots, as these attributes profoundly impact their behavior in the body, including biodistribution, toxicity, and interaction with biological systems [102 105]. Given the historical difficulty in characterizing nanomaterials and the inadequacy of traditional in vitro assays for predicting in vivo effects, this phase will be critical for developing novel characterization methods and establishing a comprehensive risk assessment plan that accounts for unique nanoscale phenomena [12 105].

Once the physical agent is defined, the focus shifts to validating the software and control systems. The mathematical rigor of the framework provides a strong foundation for simulation-based validation. Digital Twin technology, which involves creating dynamic virtual representations of physical assets, can be employed to model the human body and the nanoswarm's interactions within it [17 150]. These simulations, informed by multiscale computational models that integrate continuum mechanics, molecular dynamics, and stochastic methods, can be used to test the safety and efficacy of the control algorithms ($I_{nano}(t)$) under a vast array of physiological conditions without exposing human subjects to risk [43 150]. This aligns with the FDA's interest in using virtual models to streamline clinical trials and improve safety [150]. Concurrently, the biosensors must be individually and collectively validated. This involves rigorous bench testing to establish accuracy, precision, sensitivity, and specificity, followed by studies to assess their performance in real-world conditions, including resistance to motion artifacts and environmental interference [60 115]. Sensor fusion algorithms must be trained and validated on large, diverse datasets to ensure they can produce a reliable and accurate estimate of the state vector $\mathbf{U}(t)$.

With the hardware and software components validated in simulation and in vitro, the next step is preclinical testing in animal models. These studies are designed to evaluate the nanoswarm's pharmacokinetics, biodistribution, and toxicity profile, providing the first evidence of its safety in a living organism [31]. Long-term studies are necessary to assess the potential for immunogenicity, inflammation, or other delayed adverse effects from the nanomaterials [12]. Successful preclinical results pave the way for a phased clinical trial program, which is required for a Class III device [34]. The initial trials would likely focus on safety and feasibility in a small cohort of patients, closely monitoring for any adverse events and confirming that the device performs as intended. Subsequent trials would enroll larger groups to gather data on efficacy, comparing outcomes in patients using the nanoswarm to those receiving standard care. Throughout this process, the system's post-market surveillance plan must be activated, collecting real-world data to monitor long-term performance, detect rare adverse events, and ensure the continued safety and effectiveness of the device [34 84]. The

data generated during these phases is not just for clinical evidence; it is also the raw material for the device's adaptive learning, feeding back into the AI model to refine its performance over time, provided these updates are managed within the framework of a Predetermined Change Control Plan (PCCP) [137].

In summary, the path from the user's conceptual framework to a clinical reality is a long and arduous one, fraught with scientific, technical, and regulatory challenges. However, the framework itself provides a powerful and principled roadmap. By adopting a regulatory-first mindset, prioritizing fail-safe mechanisms, leveraging advanced simulation technologies, and planning for a comprehensive validation and clinical trial program, the vision of a safe, effective, and ethically governed nanoswarm medical assistant can be realized. The framework is not merely a description of a future technology; it is a detailed blueprint for navigating the complex gauntlet of modern medical device development, ensuring that innovation proceeds hand-in-hand with patient safety and regulatory compliance.

Reference

1. https://cdn.qwenlm.ai/qwen_url_parse_to_markdown/system00-0000-0000-0000-webUrlParser?key=eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJyZXNvdXJjZV91c2VyX2lkIjoicXdlbl91cmxfcGFyc2VfdG9fbWFya2Rvd24iLCJyZXNvdXJjZV9pZCI6InN5c3RlbTAwLTAwMDAtMDAwMC0wMDAwLXdlYlVybFBhcnNlciIsInJlc291cmNlX2NoYXRfaWQiOm51bGx9.cz1eeZEZdaQH5CgUaxwUmfEJfqTOZMoh3PbosHslSPA
2. https://cdn.qwenlm.ai/qwen_url_parse_to_markdown/system00-0000-0000-0000-webUrlParser?key=eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJyZXNvdXJjZV91c2VyX2lkIjoicXdlbl91cmxfcGFyc2VfdG9fbWFya2Rvd24iLCJyZXNvdXJjZV9pZCI6InN5c3RlbTAwLTAwMDAtMDAwMC0wMDAwLXdlYlVybFBhcnNlciIsInJlc291cmNlX2NoYXRfaWQiOm51bGx9.cz1eeZEZdaQH5CgUaxwUmfEJfqTOZMoh3PbosHslSPA
3. https://cdn.qwenlm.ai/qwen_url_parse_to_markdown/system00-0000-0000-0000-webUrlParser?key=eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJyZXNvdXJjZV91c2VyX2lkIjoicXdlbl91cmxfcGFyc2VfdG9fbWFya2Rvd24iLCJyZXNvdXJjZV9pZCI6InN5c3RlbTAwLTAwMDAtMDAwMC0wMDAwLXdlYlVybFBhcnNlciIsInJlc291cmNlX2NoYXRfaWQiOm51bGx9.cz1eeZEZdaQH5CgUaxwUmfEJfqTOZMoh3PbosHslSPA
4. A Language for Automatically Enforcing Privacy Policies https://www.cs.cmu.edu/~jyang2/papers/popl088-yang.pdf
5. Sapper: A Language for Hardware- Level Security Policy ... http://people.cs.uchicago.edu/~ftchong/papers/ASPLOS-14-sapper.pdf
6. ZKPDL: A Language-Based System for Efficient Zero- ... https://www.usenix.org/legacy/event/sec10/tech/full_papers/Meiklejohn.pdf

7. Language-Based Information-Flow Security - CS@Cornell https://www.cs.cornell.edu/andru/papers/jsac/sm-jsac03.pdf
8. FABLE: A Language for Enforcing User-defined Security Policies https://www.cs.umd.edu/~mwh/papers/fable.pdf
9. A Type System for Expressive Security Policies https://www.cs.princeton.edu/~dpw/papers/security.pdf
10. Enforcing Trace Properties by Program Transformation - Pop-Art https://pop-art.inrialpes.fr/~fradet/PDFs/POPL00.pdf
11. Nanotechnology Programs at FDA https://www.fda.gov/science-research/science-and-research-special-topics/nanotechnology-programs-fda
12. Regulatory pathways and guidelines for nanotechnology ... https://pmc.ncbi.nlm.nih.gov/articles/PMC11919859/
13. Current State of Nanotechnology in 2025 - How Advanced Is It? https://hsocialcreator.in/current-state-of-nanotechnology-in-2025-how-advanced-is-it
14. FDA's Approach to Regulation of Nanotechnology Products https://www.fda.gov/science-research/nanotechnology-programs-fda/fdas-approach-regulation-nanotechnology-products
15. Statement By John Bailey, EVP For Science CTFA On FDA ... https://www.personalcarecouncil.org/newsroom/statement-by-john-bailey-evp-for-science-ctfa-on-fda-nanotechnology-report/
16. Regulating Nanomedicine at the Food and Drug Administration https://journalofethics.ama-assn.org/article/regulating-nanomedicine-food-and-drug-administration/2019-04
17. Landscape Analysis of Adoption of Advanced ... https://www.fda.gov/media/184464/download
18. Task Force Prods FDA to Address Nanotechnology https://www.supplysidesj.com/supplement-regulations/task-force-prods-fda-to-address-nanotechnology
19. FDA Nanomaterials Final Guidance for Biological Drug ... https://natlawreview.com/article/fda-publishes-final-guidance-industry-drug-products-including-biological-products
20. FDA Provides Guidance on Advanced Manufacturing ... https://tentelemed.com/fda-provides-guidance-on-advanced-manufacturing-technologies-program/
21. When AI Technology and HIPAA Collide https://www.hipaajournal.com/when-ai-technology-and-hipaa-collide/
22. Advancing Compliance with HIPAA and GDPR in Healthcare https://pmc.ncbi.nlm.nih.gov/articles/PMC12563691/
23. HIPAA compliance for generative AI solutions on AWS https://aws.amazon.com/blogs/industries/hipaa-compliance-for-generative-ai-solutions-on-aws/
24. HIPAA and the Algorithm: What Happens When AI Gets It ... https://censinet.com/perspectives/hipaa-and-the-algorithm-what-happens-when-ai-gets-it-wrong

25. AI in Healthcare: Key HIPAA Compliance Requirements https://www.themomentum.ai/blog/ai-and-hipaa-compliance-in-healthcare-all-you-need-to-know
26. Navigating HIPAA's New Security Rule - Implications for ... https://www.aidoc.com/learn/blog/navigating-hipaas-new-security-rule-implications-for-clinical-ai/
27. AI Medical Scribe Security: Complete HIPAA Compliance ... https://www.scribehealth.ai/blog/ai-medical-scribe-security-complete-hipaa-compliance-guide-for-healthcare
28. HIPAA-Compliant LLMs: Guide to Using AI in Healthcare ... https://www.techmagic.co/blog/hipaa-compliant-llms
29. How AI is Transforming Healthcare Security & Compliance https://www.hipaavault.com/resources/ai-transforming-healthcare-security-compliance/
30. Updating HIPAA Security to Respond to Artificial Intelligence https://journal.ahima.org/page/updating-hipaa-security-to-respond-to-artificial-intelligence
31. Nanotechnology | Medical Device Regulation https://www.medical-device-regulation.eu/wp-content/uploads/2020/09/Nanotechnology_web.pdf
32. MDCG 2021-24 Guidance on classification of medical devices https://health.ec.europa.eu/system/files/2021-10/mdcg_2021-24_en_0.pdf
33. Recent regulatory developments in EU Medical Device ... https://pmc.ncbi.nlm.nih.gov/articles/PMC11883120/
34. Understanding EU Class III Medical Devices https://www.registrarcorp.com/blog/medical-devices/medical-device-regulations/understanding-eu-class-iii-medical-devices/
35. Medical Device Classification under EU MDR [Overview] https://www.greenlight.guru/blog/eu-medical-device-classification
36. EU MDR CE Marking Certification Process https://www.emergobyul.com/resources/european-medical-devices-regulation-mdr-ce-marking-regulatory-process
37. Medical Device Regulation (MDR) https://www.bsigroup.com/en-US/products-and-services/medical-devices/medical-device-regulation-mdr/
38. Explore the Changes to Medical Device Classification ... https://www.kapstonemedical.com/resource-center/blog/explore-the-changes-to-medical-device-classification-under-eu-mdr
39. Class III Medical Device - Support For EU CE Marking https://www.i3cglobal.com/class-iii-medical-device/
40. EU Medical Device Regulation (MDR) https://brightinsight.com/standards-regulations-and-certifications/eu-medical-device-regulation-mdr
41. Multiphysics modelling enhanced by imaging and artificial ... https://www.sciencedirect.com/science/article/pii/S0168365925007497
42. A Control Theory Informed Machine Learning-Based ... https://www.researchgate.net/publication/392881535_A_Control_Theory_Informed_Machine_Learning-Based_Modeling_and_Monitoring_of_Nanoparticle_Generation_Processes

43. The role of multiscale computational approaches for ... https://pmc.ncbi.nlm.nih.gov/articles/PMC2676650/

44. Advanced hybrid intelligence evaluation of nanomedicine ... https://www.nature.com/articles/s41598-025-13028-w

45. Smart Drug Delivery Systems: Technological ... https://www.jnsam.com/article_226766.html

46. Nanotechnology in medicine: a double-edged sword for ... https://healthnanotechnology.biomedcentral.com/articles/10.1186/s44301-025-00008-2

47. Control Theory and Systems Biology https://www.mdpi.com/1422-0067/25/1/365

48. Artificial Intelligence-Assisted Design of Nanomedicines for ... https://link.springer.com/article/10.1007/s12668-025-01980-w

49. Artificial intelligence in smart drug delivery systems https://pubs.rsc.org/en/content/articlehtml/2025/pm/d5pm00089k

50. Artificial Intelligence and Machine Learning Implemented ... https://spj.science.org/doi/10.34133/jbioxresearch.0016

51. Mathematical Modelling and Analysis of Nanobio-Sensors ... https://www.ijrte.org/wp-content/uploads/papers/v1i4/D0318091412.pdf

52. Editorial: Bio-Inspired Physiological Signal(s) and Medical ... https://pmc.ncbi.nlm.nih.gov/articles/PMC8586079/

53. Mathematical modeling in cancer nanomedicine: a review https://link.springer.com/article/10.1007/s10544-019-0380-2

54. Nerve Signal Transferring Mechanism and Mathematical ... https://www.mdpi.com/2504-3110/8/11/648

55. The role of mathematical models in designing ... https://www.frontiersin.org/journals/systems-biology/articles/10.3389/fsysb.2022.929426/full

56. On mathematical modeling of the propagation of a wave ... https://pmc.ncbi.nlm.nih.gov/articles/PMC10416108/

57. Foundation Models for Biosignals: A Survey https://www.techrxiv.org/doi/full/10.36227/techrxiv.175606236.62808131

58. Complex mathematical models of biology at the nanoscale https://www.academia.edu/14475410/Complex_mathematical_models_of_biology_at_the_nanoscale

59. a Lightweight Embedding Model for Biosignal Analysis https://arxiv.org/abs/2507.21875

60. Biosignal-integrated robotic systems with emerging trends in ... https://pmc.ncbi.nlm.nih.gov/articles/PMC10903439/

61. Control and Autonomy of Microrobots: Recent Progress ... https://onlinelibrary.wiley.com/doi/10.1002/aisy.202100279

62. Technology Roadmap of Micro/Nanorobots | ACS Nano https://pubs.acs.org/doi/10.1021/acsnano.5c03911

63. Deep learning for biosignal control https://iopscience.iop.org/article/10.1088/1741-2552/ac4f9a/pdf

64. NavHD: Low-Power Learning for Micro-Robotic Controls in ... https://stanford.edu/~chae/paper/navhd.pdf

65. Multimodal Field-Driven Actuation in Bioinspired Robots https://pmc.ncbi.nlm.nih.gov/articles/PMC12564142/

66. Control and Autonomy of Microbots https://pubs.aip.org/aip/acp/article-pdf/doi/10.1063/5.0195337/19706591/020028_1_5.0195337.pdf

67. Two-Dimensional Autonomous Microparticle Manipulation ... https://www.researchgate.net/publication/241637962_Two-Dimensional_Autonomous_Microparticle_Manipulation_Strategies_for_Magnetic_Microrobots_in_Fluidic_Environments

68. HIPAA Encryption Requirements - 2025 Update https://www.hipaajournal.com/hipaa-encryption-requirements/

69. Audit Protocol https://www.hhs.gov/hipaa/for-professionals/compliance-enforcement/audit/protocol/index.html

70. Security Rule Guidance Material https://www.hhs.gov/hipaa/for-professionals/security/guidance/index.html

71. HIPAA Encryption Requirements: An Updated Guide https://drata.com/blog/hipaa-encryption-requirements

72. HIPAA Audit Logs: Complete Requirements for Compliance https://www.kiteworks.com/hipaa-compliance/hipaa-audit-log-requirements/

73. HIPAA Cybersecurity Requirements: Complete 2025 Guide https://qualysec.com/hipaa-cybersecurity-requirements/

74. HIPAA Encryption Requirements Explained https://www.accountablehq.com/post/hipaa-encryption-requirements-explained

75. Understanding HIPAA Encryption Requirements: What You ... https://www.doctorsmanagement.com/blog/understanding-hipaa-encryption-requirements-what-you-need-to-know/

76. HIPAA Encryption Protocols: 2025 Updates https://censinet.com/perspectives/hipaa-encryption-protocols-2025-updates

77. Understanding the new HIPAA audit requirements https://www.paubox.com/news/understanding-the-new-hipaa-audit-requirements

78. MDR Guidance Documents - Medical Device Regulation https://www.medical-device-regulation.eu/mdr-guidance-documents/

79. Software as a Medical Device (SaMD) | MDR Compliance ... https://mantrasystems.com/eu-mdr-compliance/software-as-a-medical-device-samd

80. Software as Medical Device: New European Commission ... https://www.sidley.com/en/insights/publications/2019/12/software-as-medical-device-new-european-commission-guidance

81. EU MDR and IVDR: Classifying Medical Device Software ... https://namsa.com/resources/blog/eu-mdr-and-ivdr-classifying-medical-device-software-mdsw/

82. Compliance Requirements for Medical Device Software ... https://www.orielstat.com/blog/compliance-requirements-for-medical-device-software-and-software-as-a-medical-device-in-the-us-and-eu/

83. EU Medical Device Regulation (MDR) Compliance https://www.bgosoftware.com/blog/adapting-to-change-how-new-medical-device-regulations-are-impacting-the-health-tech-industry/

84. Ultimate Guide to Device Class Requirements under EU ... https://www.greenlight.guru/blog/device-class-requirements-eu-mdr

85. FDA's Final Cybersecurity Guidance (June 2025) https://c2a-sec.com/fdas-final-cybersecurity-guidance-june-2025-what-medical-device-manufacturers-must-do-now/

86. FDA replaces cybersecurity guidance for medical devices, ... https://www.raps.org/news-and-articles/news-articles/2025/6/fda-replaces-cybersecurity-guidance-for-medical-de

87. 2025 FDA Guidance - Cybersecurity in Medical Devices https://innolitics.com/articles/2025-cybersecurity-guidance/

88. FDA's 2025 Cybersecurity Guidance: Mastering the New ... https://excellence-consulting.services/resources/fda_cybersecurity_testing_guidance.php

89. FDA Cybersecurity Guidance 2025: What it Means for ... https://www.manifestcyber.com/blog/the-future-of-medical-device-security-is-transparent

90. Cybersecurity https://www.fda.gov/medical-devices/digital-health-center-excellence/cybersecurity

91. FDA Cybersecurity Guidance in 2025 https://bluegoatcyber.com/blog/fda-cybersecurity-guidance-in-2025-new-recommendations-just-published/

92. FDA's draft guidance on artificial intelligence (AI) and ... https://www.medcrypt.com/blog/navigate-the-fda-draft-guidance-on-artificial-intelligence-ai-and-cybersecurity

93. MedCon: Experts offer guidance on meeting FDA's ... https://www.raps.org/news-and-articles/news-articles/2025/5/medcon-experts-offer-guidance-on-meeting-fda-s-hei

94. General Principles of Software Validation - Final Guidance ... https://www.fda.gov/media/73141/download

95. Micro/Nanorobotic Swarms: From Fundamentals to ... https://pubs.acs.org/doi/10.1021/acsnano.2c11733

96. Micro- and Nanomotors: Engineered Tools for Targeted and ... https://pmc.ncbi.nlm.nih.gov/articles/PMC11912581/

97. (PDF) An Overview of Micro/Nanorobot Swarm Control https://www.researchgate.net/publication/383755573_An_Overview_of_MicroNanorobot_Swarm_Control_From_Fundamental_Understanding_to_Autonomy
98. Swarming magnetic nanorobots bio-interfaced by ... https://www.science.org/doi/10.1126/sciadv.adk7251
99. Ultrasound Doppler-guided real-time navigation of a ... https://pubmed.ncbi.nlm.nih.gov/33637532/
100. Reflections on dynamic consent in biomedical research https://pmc.ncbi.nlm.nih.gov/articles/PMC7695991/
101. Nanomedicine: Issues of Privacy and Informed Consent https://www.researchgate.net/publication/236172139_Nanomedicine_Issues_of_Privacy_and_Informed_Consent
102. The regulation of nanomaterials and nanomedicines for ... https://pubs.rsc.org/en/content/articlehtml/2020/bm/d0bm00558d
103. Dynamic consent, communication and return of results in large ... https://pmc.ncbi.nlm.nih.gov/articles/PMC10434987/
104. Opportunities and challenges of a dynamic consent-based ... https://bmcmedethics.biomedcentral.com/articles/10.1186/s12910-024-01091-3
105. Nanomedicine: Principles, Properties, and Regulatory Issues https://www.frontiersin.org/journals/chemistry/articles/10.3389/fchem.2018.00360/full
106. human nanoswarm cancer clinical https://tas.ac.uk/wp-content/uploads/2022/07/How-should-we-regulate-the-first-in-human-nanoswarm-cancer-clini.pdf
107. Enabling Remote Responder Bio-Signal Monitoring in a ... https://www.mdpi.com/1424-8220/23/1/49
108. Ex vivo validation of magnetically actuated intravascular ... https://pmc.ncbi.nlm.nih.gov/articles/PMC11099159/
109. Smart nano-bio-devices https://ibecbarcelona.eu/nanodevices/
110. Reversible Swarming and Separation of Self-Propelled ... https://www.researchgate.net/publication/271592564_Reversible_Swarming_and_Separation_of_Self-Propelled_Chemically_Powered_Nanomotors_under_Acoustic_Fields
111. Luca Benini https://www.csauthors.net/luca-benini/
112. Vector-Controlled Wheel-Like Magnetic Swarms With ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9081439/
113. Multi - dimensional micro/nanorobots with collective behaviors https://onlinelibrary.wiley.com/doi/full/10.1002/smm2.1263
114. Machine learning in biosignal analysis from wearable devices https://pubs.rsc.org/en/content/articlehtml/2025/mh/d5mh00451a

115. Synergizing Nanosensor-Enhanced Wearable Devices with ... https://pubs.acs.org/doi/10.1021/acsnano.5c04337

116. Smart nano-bio-devices https://ibecbarcelona.eu/es/nanodevices/

117. A Versatile Diffusion Model for Biomedical Signal Synthesis https://www.mdpi.com/2306-5354/11/4/299

118. Nanosensors and Microsensors for Body Fluid Monitoring https://pmc.ncbi.nlm.nih.gov/articles/PMC12154056/

119. Nano-immunosensors for the rapid and sensitive detection ... https://www.sciencedirect.com/science/article/pii/S092666902500425X

120. Wearable and flexible electrochemical sensors for sweat ... https://www.nature.com/articles/s41378-022-00443-6

121. Nanomaterial-Based Sensing Systems to Detect ... https://www.mdpi.com/1424-8220/25/11/3256

122. Epicore Biosystems | Wearable Hydration & Heat Stress Monitor https://www.epicorebiosystems.com/

123. Diving into Sweat: Advances, Challenges, and Future ... https://pubs.acs.org/doi/10.1021/acsnano.4c10344

124. Wearable chemical sensors for biomarker discovery in the ... http://www.gao.caltech.edu/uploads/2/6/7/2/26723767/sempionatto_et_al-2022-nature_reviews_chemistry.pdf

125. Nanotechnology and nanosensors in personalized ... https://www.sciencedirect.com/science/article/pii/S2214180425000066

126. Advances in Multifunctional Nanoagents and SERS-Based ... https://pmc.ncbi.nlm.nih.gov/articles/PMC12026551/

127. A Guide to HIPAA-Compliant Agentic AI for Healthcare https://www.providertech.com/hipaa-compliant-ai-for-healthcare/

128. Proposed HIPAA Security Rule Requires AI Governance https://frostbrowntodd.com/proposed-hipaa-security-rule-requires-ai-governance/

129. Artificial Intelligence in Software as a Medical Device https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-software-medical-device

130. Considerations for the Use of Artificial Intelligence To ... https://www.fda.gov/media/184830/download

131. Regulating the Use of AI in Drug Development: Legal ... https://www.fdli.org/2025/07/regulating-the-use-of-ai-in-drug-development-legal-challenges-and-compliance-strategies/

132. Evaluating AI-enabled Medical Device Performance in ... https://www.fda.gov/medical-devices/digital-health-center-excellence/request-public-comment-measuring-and-evaluating-artificial-intelligence-enabled-medical-device

133. Regulatory pathways and guidelines for nanotechnology ... https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1544393/full

134. New FDA-Guidance for Industry draft on AI https://www.gmp-compliance.org/gmp-news/new-fda-guidance-for-industry-draft-on-ai

135. FDA Publishes Its First Draft Guidance On Use of Artificial ... https://www.goodwinlaw.com/en/insights/publications/2025/01/alerts-lifesciences-aiml-fda-publishes-its-first-draft-guidance

136. JPM2025: Regulation of artificial intelligence: Navigating a ... https://www.hoganlovells.com/en/publications/jpm2025-regulation-of-artificial-intelligence-navigating-a-new-frontier-in-health-care

137. AI Medical Devices: FDA Draft Guidance, TPLC & PCCP ... https://www.complizen.ai/post/fda-ai-medical-device-regulation-2025

138. Protecting Patients from Medical Device Cyber Threats, ... https://breached.company/navigating-the-digital-frontier-protecting-patients-from-medical-device-cyber-threats-including-the-mind-itself/

139. Enabling Dynamic Consent Through AI and Blockchain https://pubmed.ncbi.nlm.nih.gov/41041799/

140. Artificial intelligence enhanced sensors - PubMed Central - NIH https://pmc.ncbi.nlm.nih.gov/articles/PMC10394931/

141. Closed Loop AI Systems pave the way for personalised ... https://spyro-soft.com/blog/healthcare/closed-loop-ai-systems-pave-the-way-for-personalised-medicine

142. Blockchain, consent and prosent for medical research https://jme.bmj.com/content/47/4/244

143. How To Implement Fail-Safe Mechanisms In Medical Nanorobots https://eureka.patsnap.com/report-how-to-implement-fail-safe-mechanisms-in-medical-nanorobots

144. Balancing multi-stakeholder perspectives on AI in healthcare https://pubmed.ncbi.nlm.nih.gov/40680319/

145. Building an AI Governance Practice in a Fortune 500 ... https://medium.com/@adnanmasood/building-an-ai-governance-practice-in-a-fortune-500-healthcare-company-0a87ce995e2c

146. WHO releases AI ethics and governance guidance for ... https://www.who.int/news/item/18-01-2024-who-releases-ai-ethics-and-governance-guidance-for-large-multi-modal-models

147. AI Governance in Health Systems: Aligning Innovation ... https://healthpolicy.duke.edu/publications/ai-governance-health-systems-aligning-innovation-accountability-and-trust

148. Responsible AI Governance in Healthcare: Who Signs Off? https://www.lumenova.ai/blog/responsible-ai-governance-healthcare/

149. Health Care Artificial Intelligence Code of Conduct https://nam.edu/our-work/programs/leadership-consortium/health-care-artificial-intelligence-code-of-conduct/

150. NSF, NIH and FDA support research in digital twin ... https://www.nsf.gov/news/nsf-nih-fda-support-research-digital-twin-technology

151. As the FDA Tackles a Complex Mission Investing in Digital ... https://governmenttechnologyinsider.com/as-the-fda-tackles-a-complex-mission-investing-in-digital-twin-technology-enables-success/

152. PrecisionFDA: A Sandbox for Innovative and https://www.fda.gov/media/182815/download

153. FDA Would Like to Join You in the Sandbox When ... https://www.thefdalawblog.com/2025/03/fda-would-like-to-join-you-in-the-sandbox-when-developing-ai-enabled-devices/

154. A Sandbox for Innovative Collaborative Omics Advancement https://www.fda.gov/media/181590/download

155. Signal management | European Medicines Agency (EMA) https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/signal-management

156. Leveraging real-world data for safety signal detection and risk ... https://pmc.ncbi.nlm.nih.gov/articles/PMC12576344/

157. Digital Health Technologies for Remote Data Acquisition in ... https://www.fda.gov/media/155022/download

158. Advances in Multivariate and Multiscale Physiological ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9774626/

159. Multidimensional Processes - IEEE Pulse https://www.embs.org/pulse/articles/multidimensional-processes/

160. Feature-Based Information Retrieval of Multimodal ... https://www.mdpi.com/2079-6374/12/12/1182

161. UNIT 1 - INTRODUCTION TO BIOMEDICAL SIGNALS https://sist.sathyabama.ac.in/sist_coursematerial/uploads/SBMA5202.pdf

162. Artificial intelligence on biomedical signals: technologies, ... https://link.springer.com/article/10.1007/s44258-024-00043-1

163. Deep learning for biosignal control: insights from basic to ... https://iopscience.iop.org/article/10.1088/1741-2552/ac4f9a

164. Multimodal biomedical AI | Nature Medicine https://www.nature.com/articles/s41591-022-01981-2

165. A decade of review in global regulation and research of ... https://pmc.ncbi.nlm.nih.gov/articles/PMC12310608/

166. Global Harmonization of Artificial Intelligence-Enabled ... https://www.sciencedirect.com/science/article/pii/S294976122400124X

167. Latest EMA, FDA and ICH Guidelines Regarding Use of AI ... https://www.vitrana.com/latest-ema-fda-and-ich-guidelines-regarding-use-of-ai-in-pharmacovigilance/

168. Artificial intelligence in pharmacovigilance https://cioms.ch/wp-content/uploads/2022/05/CIOMS-WG-XIV_Draft-report-for-Public-Consultation_1May2025.pdf

169. Leveraging real-world data for safety signal detection and ... https://www.frontiersin.org/journals/drug-safety-and-regulation/articles/10.3389/fdsfr.2025.1626822/pdf

170. Large-scale Training of Foundation Models for Wearable ... https://arxiv.org/html/2312.05409v2

171. Large-scale Training of Foundation Models for Wearable ... https://openreview.net/forum?id=pC3WJHf51j

172. Switching state-space modeling of neural signal dynamics https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1011395

173. HMAC-SHA512 vs BLAKE3 - A Comprehensive Comparison https://mojoauth.com/compare-hashing-algorithms/hmac-sha512-vs-blake3/

174. Classification of Hash Functions Suitable for Real-life Systems https://csrc.nist.rip/groups/ST/hash/documents/MATSUO_NISTWS_f0728_3.pdf

175. Bridging the Gap: Decrypting Cryptography https://www.medcrypt.com/cybersecurity-whitepapers/whitepapers-decrypting-cryptography-medical-devices

176. FDA Guidelines For Medical Device Security Requirements https://qualysec.com/fda-guidelines-for-medical-device-security-requirements-2023/

177. Blockchain integration in healthcare - PubMed Central https://pmc.ncbi.nlm.nih.gov/articles/PMC11082361/

178. An analysis of the ethical challenges of blockchain ... https://www.sciencedirect.com/science/article/pii/S2666307421000206

179. The Use of Blockchain Technology in the Health Care Sector https://medinform.jmir.org/2022/1/e17278/

180. Utilizing Blockchain and Smart Contracts for Enhanced ... https://arxiv.org/html/2407.17765v1

181. Blockchain-Aided and Privacy-Preserving Data ... http://ieeexplore.ieee.org/document/9964420/

182. Unraveling a blockchain-based framework towards patient ... https://pmc.ncbi.nlm.nih.gov/articles/PMC10102703/

183. Blockchain in Healthcare https://gkc.himss.org/resources/blockchain-healthcare

184. A Multi-Party Functional Signatures Scheme for Private ... https://www.mdpi.com/2410-387X/7/2/21

185. Blockchain applications in health insurance: a review ... https://www.frontiersin.org/journals/blockchain/articles/10.3389/fbloc.2025.1699290/full

186. Blockchain Ethical Design Framework for Healthcare https://gbaglobal.org/wp-content/uploads/2020/12/Blockchain-Ethical-Design-Framework-for-Healthcare-Final-rev1.pdf

187. HIPAA Compliance AI in 2025: Critical Security ... https://www.sprypt.com/blog/hipaa-compliance-ai-in-2025-critical-security-requirements

188. HIPAA Security Rule | Prepare for Compliance Changes in ... https://www.hipaavault.com/resources/hipaa-security-rule-updates-2025/

189. 2025 HIPAA Updates: Key Changes Every Organization ... https://www.metricstream.com/blog/hipaa-updates-2025-key-changes.html

190. Understanding the 2025 HIPAA Security Rule Updates https://www.cyberdefensemagazine.com/understanding-the-2025-hipaa-security-rule-updates-a-comprehensive-analysis-of-healthcare-cybersecurity-enhancements/

191. Communication protocols integrating wearables ... https://www.sciencedirect.com/science/article/pii/S2666998623001448

192. Leveraging network structure in nonlinear control - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC9526710/

193. Neural ODEs as Feedback Policies for Nonlinear Optimal ... https://arxiv.org/abs/2210.11245

194. Computing robust control invariant sets of constrained ... https://www.sciencedirect.com/science/article/abs/pii/S0098135420312205

195. University of Groningen Feedback linearization of ... https://research.rug.nl/files/210273466/Intl_J_Robust_Nonlinear_2021_Chen_Feedback_linearization_of_nonlinear_differential_algebraic_control_systems.pdf

196. Neural ODEs as Feedback Policies for Nonlinear Optimal ... https://www.researchgate.net/publication/364507996_Neural_ODEs_as_Feedback_Policies_for_Nonlinear_Optimal_Control

197. Faster deterministic Feedback Vertex Set https://www.mimuw.edu.pl/~kociumaka/files/ipl2.pdf

198. Neural ODEs as Feedback Policies for Nonlinear Optimal ... https://ui.adsabs.harvard.edu/abs/2022arXiv221011245O/abstract

199. Solving Directed Feedback Vertex Set by Iterative Reduction ... https://drops.dagstuhl.de/storage/00lipics/lipics-vol265-sea2023/LIPIcs.SEA.2023.10/LIPIcs.SEA.2023.10.pdf

200. PACE solver description: DreyFVS https://inria.hal.science/hal-03920659/file/PACE_2022___DreyFVS.pdf

201. An optimal approximation algorithm for Feedback Vertex ... https://www.youtube.com/watch?v=DT3ty9o_9bw

202. What Can Systems Theory of Networks Offer to Biology? https://pmc.ncbi.nlm.nih.gov/articles/PMC3386158/

203. Target control of complex networks | Nature Communications https://www.nature.com/articles/ncomms6415

204. Target controllability with minimal mediators in complex ... https://www.sciencedirect.com/science/article/pii/S0888754320311861

205. Controllability and Its Applications to Biological Networks https://www.sciopen.com/article/10.1007/s11390-019-1896-x

206. Local controllability of complex networks https://www.aimspress.com/article/doi/10.3934/mmc.2021010?viewType=HTML

207. (PDF) Controllability of complex networks https://www.researchgate.net/publication/51117462_Controllability_of_complex_networks

208. Control principles of complex systems | Rev. Mod. Phys. https://link.aps.org/doi/10.1103/RevModPhys.88.035006

209. Low-dimensional controllability of brain networks https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1012691

210. Control of multilayer biological networks and applied to target ... https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-019-2841-2

211. BLAKE-512 in NodeJS - Hashing https://mojoauth.com/hashing/blake-512-in-nodejs/

212. Statistical analysis of enhanced SDEx encryption method ... https://www.researchgate.net/publication/396811078_Statistical_analysis_of_enhanced_SDEx_encryption_method_based_on_BLAKE3_hash_function